The Combination Therapy of Oncolytic Virotherapy

Overview

Journal Front Pharmacol

Date 2024 May 10

PMID 38725667

Authors

Yue Wang

Mengying Zhu

Huanyu Chi

Yang Liu

Guilin Yu

Affiliations

Soon will be listed here.

Abstract

Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction. However, the efficacy of oncolytic viruses as a monotherapy often falls short of expectations. Consequently, combining oncolytic viruses with traditional treatments to achieve synergistic effects has emerged as a promising direction for the development of oncolytic virus therapies. This article provides a comprehensive review of the current progress in preclinical and clinical trials exploring the combination therapies involving oncolytic viruses. Specifically, we discuss the combination of oncolytic viruses with immune checkpoint inhibitors, chemotherapy, targeted therapy, and cellular therapy. The aim of this review is to offer valuable insights and references for the further advancement of these combination strategies in clinical applications. Further research is necessary to refine the design of combination therapies and explore novel strategies to maximize the therapeutic benefits offered by oncolytic viruses.

Citing Articles

A Novel Oncolytic Virus Formulation Based on Mesenchymal Stem Cell-Derived Vesicles for Tumor Therapy.

Zeng F, Huang Y, Xu B, Yao L, Zhang Y, Gao Z J Cancer. 2025; 16(3):700-707.

PMID: 39781350 PMC: 11705066. DOI: 10.7150/jca.104066.

Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas.

Melendez-Vazquez N, Gomez-Manzano C, Godoy-Vitorino F Viruses. 2024; 16(11).

PMID: 39599889 PMC: 11599061. DOI: 10.3390/v16111775.

References

Wang L, Ning J, Wakimoto H, Wu S, Wu C, Humphrey M . Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Mol Ther Oncolytics. 2019; 13:58-66. PMC: 6468160. DOI: 10.1016/j.omto.2019.03.008. View

Chen L, Zuo M, Zhou Q, Wang Y . Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front Immunol. 2024; 14:1308890. PMC: 10758479. DOI: 10.3389/fimmu.2023.1308890. View

Enow J, Sheikh H, Rahman M . Tumor Tropism of DNA Viruses for Oncolytic Virotherapy. Viruses. 2023; 15(11). PMC: 10675630. DOI: 10.3390/v15112262. View

Park A, Fong Y, Kim S, Yang J, Murad J, Lu J . Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Transl Med. 2020; 12(559). PMC: 9126033. DOI: 10.1126/scitranslmed.aaz1863. View

Jonker D, Tang P, Kennecke H, Welch S, Cripps M, Asmis T . A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clin Colorectal Cancer. 2018; 17(3):231-239.e7. DOI: 10.1016/j.clcc.2018.03.001. View

Driscoll C, Schuelke M, Kottke T, Thompson J, Wongthida P, Tonne J . APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat Commun. 2020; 11(1):790. PMC: 7005822. DOI: 10.1038/s41467-020-14568-7. View

Malfitano A, Di Somma S, Iannuzzi C, Pentimalli F, Portella G . Virotherapy: From single agents to combinatorial treatments. Biochem Pharmacol. 2020; 177:113986. DOI: 10.1016/j.bcp.2020.113986. View

Puzanov I, Milhem M, Minor D, Hamid O, Li A, Chen L . Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016; 34(22):2619-26. PMC: 7189507. DOI: 10.1200/JCO.2016.67.1529. View

Kelly C, Antonescu C, Bowler T, Munhoz R, Chi P, Dickson M . Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA Oncol. 2020; 6(3):402-408. PMC: 6990941. DOI: 10.1001/jamaoncol.2019.6152. View

10.

Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martin M, Alvarez R, Macarulla T, Riesco-Martinez M . Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer. 2022; 10(3). PMC: 8961117. DOI: 10.1136/jitc-2021-003255. View

11.

Lin D, Shen Y, Liang T . Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023; 8(1):156. PMC: 10090134. DOI: 10.1038/s41392-023-01407-6. View

12.

Kim S, Park A, Chaurasiya S, Kang S, Lu J, Yang A . Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Mol Cancer Ther. 2020; 20(1):173-182. PMC: 7790874. DOI: 10.1158/1535-7163.MCT-20-0405. View

13.

Barton K, Siddiqui F, Pompa R, Freytag S, Khan G, Dobrosotskaya I . Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Mol Ther Oncolytics. 2021; 20:94-104. PMC: 7851493. DOI: 10.1016/j.omto.2020.11.006. View

14.

Bommareddy P, Aspromonte S, Zloza A, Rabkin S, Kaufman H . MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med. 2018; 10(471). PMC: 7593827. DOI: 10.1126/scitranslmed.aau0417. View

15.

Du Z, Whitt M, Baumann J, Garner J, Morton C, Davidoff A . Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1. J Interferon Cytokine Res. 2012; 32(8):368-77. PMC: 3422054. DOI: 10.1089/jir.2012.0002. View

16.

Li F, Sheng Y, Hou W, Sampath P, Byrd D, Thorne S . CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 2020; 8(1). PMC: 7057442. DOI: 10.1136/jitc-2019-000131. View

17.

Chen T, Ding X, Liao Q, Gao N, Chen Y, Zhao C . IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J Immunother Cancer. 2021; 9(1). PMC: 7843316. DOI: 10.1136/jitc-2020-001647. View

18.

Nguyen T, Ramsay L, Ahanfeshar-Adams M, Lajoie M, Schadendorf D, Alain T . Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. Clin Cancer Res. 2021; 27(12):3432-3442. DOI: 10.1158/1078-0432.CCR-20-3365. View

19.

Yao X, Jing T, Geng Q, Pang M, Zhao X, Li S . Dual analysis of wild-type and attenuated and host cell transcriptomes revealed novel virus-host cell interactions. mSphere. 2023; 8(6):e0039823. PMC: 10732022. DOI: 10.1128/msphere.00398-23. View

20.

Mamola J, Chen C, Currier M, Cassady K, Lee D, Cripe T . Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy. Mol Ther Oncolytics. 2023; 29:118-124. PMC: 10209482. DOI: 10.1016/j.omto.2023.04.008. View